JP6563816B2 - 増強された導入遺伝子発現およびプロセシング - Google Patents

増強された導入遺伝子発現およびプロセシング Download PDF

Info

Publication number
JP6563816B2
JP6563816B2 JP2015555816A JP2015555816A JP6563816B2 JP 6563816 B2 JP6563816 B2 JP 6563816B2 JP 2015555816 A JP2015555816 A JP 2015555816A JP 2015555816 A JP2015555816 A JP 2015555816A JP 6563816 B2 JP6563816 B2 JP 6563816B2
Authority
JP
Japan
Prior art keywords
mar
seq
expression
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015555816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504922A (ja
JP2016504922A5 (enExample
Inventor
フォルン，ヴァレリー ル
フォルン，ヴァレリー ル
メルモ，ニコラス
レガメー，アレキサンドレ
ブセタ，モンセ
レイ，デボラ
ハーラギー，ニアム
コスティルコ，カジャ
ジロー，ピエール‐アラン
カラブレーゼ，デヴィッド
Original Assignee
セレクシス エス．エー．
セレクシス エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクシス エス．エー．, セレクシス エス．エー． filed Critical セレクシス エス．エー．
Publication of JP2016504922A publication Critical patent/JP2016504922A/ja
Publication of JP2016504922A5 publication Critical patent/JP2016504922A5/ja
Application granted granted Critical
Publication of JP6563816B2 publication Critical patent/JP6563816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2015555816A 2013-02-01 2014-02-01 増強された導入遺伝子発現およびプロセシング Active JP6563816B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US61/759,802 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US61/800,244 2013-03-15
US201361806634P 2013-03-29 2013-03-29
US61/806,634 2013-03-29
PCT/IB2014/000100 WO2014118619A2 (en) 2013-02-01 2014-02-01 Enhanced transgene expression and processing

Publications (3)

Publication Number Publication Date
JP2016504922A JP2016504922A (ja) 2016-02-18
JP2016504922A5 JP2016504922A5 (enExample) 2017-02-16
JP6563816B2 true JP6563816B2 (ja) 2019-08-21

Family

ID=50239688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555816A Active JP6563816B2 (ja) 2013-02-01 2014-02-01 増強された導入遺伝子発現およびプロセシング

Country Status (20)

Country Link
US (1) US11898154B2 (enExample)
EP (2) EP2951309B1 (enExample)
JP (1) JP6563816B2 (enExample)
KR (1) KR102235603B1 (enExample)
CN (2) CN120718957A (enExample)
AU (2) AU2014210856B2 (enExample)
CA (1) CA2898878C (enExample)
DK (2) DK2951309T3 (enExample)
ES (2) ES2717175T3 (enExample)
FI (1) FI3536797T3 (enExample)
HU (2) HUE061494T2 (enExample)
IL (1) IL240198B (enExample)
LT (1) LT2951309T (enExample)
PL (2) PL3536797T3 (enExample)
PT (2) PT2951309T (enExample)
RU (1) RU2711505C9 (enExample)
SG (2) SG10201803758XA (enExample)
SI (1) SI2951309T1 (enExample)
WO (1) WO2014118619A2 (enExample)
ZA (1) ZA201506419B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576269B (zh) * 2014-04-01 2020-08-28 三生国健药业（上海）股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
US20180265894A1 (en) * 2015-10-06 2018-09-20 National University Corporation Okayama University Gene Expression Cassette And Product Thereof
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
WO2017109177A1 (en) 2015-12-24 2017-06-29 Selexis S.A. Improved eukaryotic cells for protein manufacturing and methods of making them
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
WO2017191165A1 (en) * 2016-05-03 2017-11-09 Lonza Ltd Modulation of lipid metabolism for protein production
JP7382138B2 (ja) * 2016-10-03 2023-11-16 第一三共株式会社 Ｈｓｐａ５遺伝子のプロモーター
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
JP7240749B2 (ja) * 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
WO2019219947A1 (en) * 2018-05-18 2019-11-21 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
US20210343368A1 (en) * 2018-09-05 2021-11-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method for Engineering Synthetic Cis-Regulatory DNA
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
US20230193341A1 (en) 2018-10-24 2023-06-22 Selexis Sa Expression systems, recombinant cells and uses thereof
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
US12404527B2 (en) * 2018-12-24 2025-09-02 Selexs S.A. Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
AU2020248453A1 (en) * 2019-03-27 2021-10-28 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
EP4041895A1 (en) * 2019-10-10 2022-08-17 The Regents of the University of California Methods to stabilize mammalian cells
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
US20230046668A1 (en) 2019-12-24 2023-02-16 Selexis S.A. Targeted integration in mammalian sequences enhancing gene expression
KR102937659B1 (ko) * 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用
CN115896227A (zh) * 2022-12-20 2023-04-04 西北农林科技大学 一种鉴定外源基因整合位点以增强转基因表达的方法
GB202305637D0 (en) 2023-04-17 2023-05-31 Macomics Ltd Transposons, vectors and genetically engineered cells
GB202415693D0 (en) 2024-10-24 2024-12-11 Macomics Ltd Genetically-engineered cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
JP3656277B2 (ja) * 1995-05-17 2005-06-08 味の素株式会社 組換えｄｎａ法によるトランスグルタミナーゼの効率的製造法
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2004065581A2 (en) * 2003-01-15 2004-08-05 Discovery Genomics, Inc. Transposon-insulator element delivery systems
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2007021353A2 (en) * 2005-06-10 2007-02-22 Genentech, Inc. Improving antibody expression using vectors containing insulator elements
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
CN102575264A (zh) * 2009-09-18 2012-07-11 瑟莱克斯公司 增加的转基因表达和加工的产品和方法

Also Published As

Publication number Publication date
KR102235603B1 (ko) 2021-04-05
CN120718957A (zh) 2025-09-30
SG11201505487UA (en) 2015-08-28
HUE061494T2 (hu) 2023-07-28
CN105073995A (zh) 2015-11-18
RU2711505C2 (ru) 2020-01-17
WO2014118619A2 (en) 2014-08-07
FI3536797T3 (fi) 2023-03-23
HK1216323A1 (en) 2016-11-04
PL3536797T3 (pl) 2023-09-11
DK3536797T5 (da) 2024-09-02
EP2951309B1 (en) 2019-01-30
IL240198A0 (en) 2015-09-24
DK2951309T3 (en) 2019-04-23
EP3536797B1 (en) 2023-01-04
ZA201506419B (en) 2017-02-22
ES2717175T3 (es) 2019-06-19
AU2019250224A1 (en) 2019-11-07
EP3536797A1 (en) 2019-09-11
PT2951309T (pt) 2019-04-03
ES2940433T3 (es) 2023-05-08
AU2014210856B2 (en) 2019-10-24
RU2711505C9 (ru) 2020-08-12
CA2898878A1 (en) 2014-08-07
US20150361451A1 (en) 2015-12-17
DK3536797T3 (da) 2023-04-03
AU2019250224B2 (en) 2022-05-12
CA2898878C (en) 2020-04-28
AU2014210856A1 (en) 2015-07-30
EP2951309A2 (en) 2015-12-09
PL2951309T3 (pl) 2019-06-28
WO2014118619A3 (en) 2014-10-30
SG10201803758XA (en) 2018-06-28
RU2015127667A (ru) 2017-03-06
HUE043103T2 (hu) 2019-08-28
IL240198B (en) 2019-10-31
KR20150123803A (ko) 2015-11-04
SI2951309T1 (sl) 2019-04-30
LT2951309T (lt) 2019-03-25
JP2016504922A (ja) 2016-02-18
US11898154B2 (en) 2024-02-13
PT3536797T (pt) 2023-03-15

Similar Documents

Publication Publication Date Title
CA2898878C (en) Enhanced transgene expression and processing
Luke et al. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system
US20120231449A1 (en) Products and methods for enhanced transgene expression and processing
Ley et al. MAR elements and transposons for improved transgene integration and expression
US9551009B2 (en) Transcription unit and use thereof in expression vectors
US20210403924A1 (en) Method for selecting cells based on CRISPR/Cas-mediated integration of a detectable tag to a target protein
JP2018537986A (ja) タンパク質製造用の改善された真核細胞およびそれらの作製方法
Ahmadi et al. Evaluating the efficiency of phiC31 integrase‐mediated monoclonal antibody expression in CHO cells
Oliviero et al. Generation of a host cell line containing a MAR‐rich landing pad for site‐specific integration and expression of transgenes
EP3901266A1 (en) Super-enhancers for recombinant gene expression in cho cells
JP2011504741A (ja) 新規組換え配列
RU2808756C1 (ru) Улучшенные экспрессия и процессинг трансгена
US9512230B2 (en) Transcription units and the use thereof in expression vectors
HK40007175B (en) Enhanced transgene expression and processing
HK40007175A (en) Enhanced transgene expression and processing
HK1216323B (en) Enhanced transgene expression and processing
JP2026512866A (ja) 遺伝子発現構築物のためのスペーサー
TWI475109B (zh) 通過抑制報告基因表現量的手段進行高產量細胞株選殖之策略

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190725

R150 Certificate of patent or registration of utility model

Ref document number: 6563816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250